Status:
COMPLETED
Exploring Biomarkers for Depression
Lead Sponsor:
Wyss Institute at Harvard University
Collaborating Sponsors:
Massachusetts General Hospital
Martinos Center for Biomedical Imaging
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18-65 years
Brief Summary
The purpose of this research is to explore objective biomarkers in voice, physiological, motor, and brain imaging signals that may one day be used to complement clinical evaluation and treatment of de...
Detailed Description
The hypothesis for our work is that dynamical fluctuations of biological signals, such as, voice, video, pulse rate, oxygen saturation, skin temperature, skin conductivity, motor response, magnetoence...
Eligibility Criteria
Inclusion
- Treatment Group
- Men or women age 18-65;
- Written informed consent;
- Meet DSM-IV criteria (by Structured Clinical Interview for DSM-IV - SCID-I/P) for current major depressive episode (MDE);
- Hamilton Rating Scale for Depression (HAM-D-17) baseline score ≥ 16.
- Treatment Group
Exclusion
- Subjects whose first language is not English;
- In women, pregnancy, plans to conceive, or unwillingness to comply with birth control requirements;
- Subjects with a baseline Clinical Global Impressions-Severity score of 6 or 7;
- Subjects with suicidal ideation where outpatient treatment is determined unsafe by the clinician. These subjects will be immediately referred to appropriate clinical treatment;
- Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease;
- History of seizure disorder;
- History or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, including alcohol, active within the last 12 months;
- Subjects with mood congruent or mood incongruent psychotic features;
- Clinical or laboratory evidence of hypothyroidism;
- Positive urine drug screen at evaluation visit;
- Electro Convulsive Therapy (ECT) during the last year;
- Subjects who have failed to respond during the course of their current major depressive episode to a trial of escitalopram (at least 40mg/day for six weeks or more)
- History of intolerance to citalopram or escitalopram;
- Subjects requiring excluded medications including antidepressants, anorexics, antiarrhythmics, and other psychotropic agents (including lithium, benzodiazepine sedatives, other sedatives, and anti-seizure medications), beta-blockers (such as metoprolol or propranolol) ketoconazole, itraconazole, fluconazole, erythromycin, omeprazole, cimetidine, dehydroepiandrosterone (DHEA), entacapone, hydroxytryptophan (5-HTP), ginkgo, St. John's Wort (hypercium), naratriptan, rizatriptan, sibutramine, zolmitriptan and warfarin (Coumadin).
- Subjects who have failed two or more adequate antidepressant trials during the current Major Depressive Episode (MDE)
- If a subject is deemed eligible from the above criteria, there is additional exclusion criteria required to participate in Martinos Center study visits, listed below. Subjects meeting any of the below criteria will not be allowed to participate in visits to the Martinos Center.
- Subjects of weight above 300 lbs. (limit for 1.5T Siemens Sonata whole body scanner used in MRI data acquisition);
- History of significant head trauma (unconsciousness for 10 minutes or longer);
- Surgical aneurysm clips;
- Cardiac pacemaker;
- Prosthetic heart valve;
- Use of a neurostimulator;
- Implanted pumps;
- Cochlear implants;
- Metal rods, plates, or screws in the body, or metal foil medical skin patches that cannot be removed;
- IUD;
- Previous head surgery;
- Hearing aid;
- Non-removable dentures, root canals, dental implants, bridges, and wires in the mouth;
- Currently breastfeeding;
- Meniere's Disease;
- Metal (shiny) tattoos or metal body jewelry that cannot be removed;
- Claustrophobia;
- Abnormal hearing;
- Glasses with vision correction greater than +/- 6 diopters.
- Healthy/Control Group Inclusion Criteria:
- Men or Women, ages 18-65;
- Written informed consent;
- QIDS-SR score of \< 8 at Screening Visit;
- Agrees to, and is eligible for, all biomarkers procedures (M/EEG, MRI, physiological recordings);
- Healthy/Control Group
Key Trial Info
Start Date :
August 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 14 2017
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT01424111
Start Date
August 1 2011
End Date
October 14 2017
Last Update
May 1 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Depression Clinical and Research Program, MGH
Boston, Massachusetts, United States, 02114